Clinical Report: Exploring Advanced Topical Treatments for Atopic Dermatitis

Overview

This review highlights that patients with atopic dermatitis (AD) applying topical therapies in clinical trials often present with high disease burden. The findings indicate that the disease burden in these patients is comparable to those in pivotal trials for systemic therapies.

Background

Atopic dermatitis is a chronic inflammatory skin condition that significantly impacts patients' quality of life due to symptoms like itch and pain. Traditional topical treatments have limitations, prompting the exploration of advanced non-corticosteroid therapies. Understanding the baseline disease severity in patients receiving these treatments is crucial for optimizing therapeutic strategies.

Data Highlights

No numerical data available in the source material.

Key Findings

• Many patients with AD in topical therapy RCTs reported high disease burden.
• Patient-reported outcomes in topical therapy RCTs overlapped with those in systemic therapy trials.
• Clinician-rated and patient-reported measures are essential for assessing disease severity.
• Topical therapies are being evaluated alongside systemic therapies for their efficacy in moderate to severe AD.

Clinical Implications

Clinicians should consider the high disease burden reported by patients using topical therapies when assessing treatment options.

Conclusion

Advanced topical therapies may expand the treatment landscape for patients with significant disease burden.

Related Resources & Content

1. Dermatology and Therapy, 2026 -- Comparative Data on Long-Term Efficacy of Biologics in Moderate-to-Severe AD
2. Dermatology and Therapy, 2026 -- Achieving Canadian Treat-to-Target Criteria in Moderate-to-Severe Atopic Dermatitis
3. Dermatology and Therapy, 2026 -- Lebrikizumab ADvocate1 and 2 Monotherapy and ADjoin Trials
4. Focused update: Guidelines of care for the management of atopic dermatitis in adults - PubMed
5. conexiant — AD Pain, Sleep Scales Validated in Phase 3 Trials
6. Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children
7. Ruxolitinib cream improves outcomes in atopic dermatitis: An updated systematic review
8. Focused update: Guidelines of care for the management of atopic dermatitis in adults - PubMed